Member Info for ROCKZ

It’s all legal, don’t worry.
All will come good for Accustem and Tils.

Main market now Shiraz don’t forget, not that it’s made any difference.
I think we will be just fine on the Nasdaq, best place for us. Like most, I’ve done my buying in TILS and didn’t expect to see these levels again but here we are.

Scott, check that your broker allows you to trade US stocks, some don’t so you may need to do a transfer.
Otherwise your shares may be sold on your behalf.

The share price still seems massively undervalued to me at these levels.
The Nasdaq listing will prove a blessing and there are life changing amounts to be made here.
Medium and long term holders have loaded up and they building blocks continue to be placed on this $1 billion plus company in the making.

Come on Jack, smile fella. Good couple of days for the company after a barren run. And the suns out!

Happy days, RNS out, things are moving quickly. Nasdaq listing on the 21st October. Real value will come through.

Same here Lurking, bit frustrating.
Same as the TILS investment experience at the moment! Just need to suck it up and wait for sunnier days.

Cloudy, it remains to be seen what their strategy is.
SPARE is obviously superior to StemprintER however there must be a reason why they aren’t just going all out with SPARE. I’m sure we will find out soon.

https://www.globenewswire.com/en/news-release/2020/05/29/2040672/0/en/Tiziana-Life-Sciences-announces-presentation-of-StemPrintER-a-superior-prognostic-test-as-compared-to-Oncotype-DX-to-predict-breast-cancer.html

Cloudy, they have confirmed that SPARE is better.
Whether it is ready to roll out straight away on a larger scale, we don’t know.

The product is ready to be used as a prognostic test.
That’s StemprintER. I’m not sure if SPARE is quite ready, it was a little behind StemprintER in development but basically an improved version.
Going by the SEC filing which offered a bit of company strategy, expect the test to be issued to potential users with no profit in mind within the first year.
The lab was being set up in Italy last time we heard.

Still here, got in for an early morning top up of £1000 in the early 60’s and now watching it slide into the 50’s! Relentless stuff!

Some bullet points from the presentation last night:
* Cash burn $1.1 m a month
* Cash in bank $48m
* Foralumab Covid Phase 2 trial to start in Brazil Sept/October
* Foralumab Crohns oral trial to start Sept/Oct
*Milciclib progressing and being re-purposed (the reason Dr Tom Adam’s was brought in from Cardiff oncology).
* TZLS501 on track development wise. Covid is potentially still on the table for this but at some point the decision will have to be made whether to concentrate on lung cancer only or continue on the Covid path.
* KS sees Foralumab as being ideal for the take home therapy market.
* No news from the UK government ref. The take home therapy application. Either way, successful or not the company see this as the correct path to continue on.
* Accustem will list on the NASDAQ.

Maybe they have done so to play the pink sheets?

Hightower have been selling down, (-0.12%).

They normally seem to drop some decent news before these investor calls.
They can employ someone within the IR department at anytime. It is needed.

Investor call in 8 days time.
Got to expect news before then..

The current share price does not reflect a company in Phase 2 trials.
Cloudy, I’m not saying you’re wrong, I read the clinical trial update the same way.
I do think we need clarification on this though to know exactly where we’re at.

Cloudy, GC has already stated that he will be recruiting within investor relations.
Investor relations is important for maintaining relations with existing investors and also building confidence for new investment.
Some of these subjects are ambiguous, as proven by this message board and it will be beneficial to have someone solely concentrated on IR to provide definitive answers to our questions.

Maybe the first trial will be classed as Phase 2a and the second trial Phase 2b?
The sooner someone is appointed to the specific role of investor relations the better.
Questions like this will be cleared up.
Good to see Foralumab being listed on the clinical trials website though.